Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

DP Petrylak; Ronald de Wit; KN Chi; A Drakaki; CN Sternberg; H Nishiyama; D Castellano; SA Hussain; A Flechon; A Bamias; EY Yu; MS van der Heijden; N Matsubara; B Alekseev; A Necchi; L Geczi; YC Ou; HS Coskun; WP Su; J Bedke; G Gakis; IJ Percent; JL Lee; M Tucci; A Semenov; F Laestadius; A Peer; G Tortora; S Safina; XG del Muro; A Rodriguez-Vida; I Cicin; H Harputluoglu; ST Tagawa; U Vaishampayan; JB Aragon-Ching; O Hamid; AM Liepa; S Wijayawardana; F Russo; RA Walgren; AH Zimmermann; RR Hozak; KM Bell-McGuinn; T Powles

doi:10.1016/s1470-2045(19)30668-0

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

DP Petrylak, Ronald de Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, D Castellano, SA Hussain, A Flechon, A Bamias, EY Yu, MS van der Heijden, N Matsubara, B Alekseev, A Necchi, L Geczi, YC Ou, HS Coskun, WP Su, J BedkeG Gakis, IJ Percent, JL Lee, M Tucci, A Semenov, F Laestadius, A Peer, G Tortora, S Safina, XG del Muro, A Rodriguez-Vida, I Cicin, H Harputluoglu, ST Tagawa, U Vaishampayan, JB Aragon-Ching, O Hamid, AM Liepa, S Wijayawardana, F Russo, RA Walgren, AH Zimmermann, RR Hozak, KM Bell-McGuinn, T Powles

Medical Oncology

Research output: Contribution to journal › Article › Academic › peer-review

66 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	105-120
Number of pages	16
Journal	Lancet Oncology
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/s1470-2045(19)30668-0
Publication status	Published - 2020

Research programs

EMC OR-01

Access to Document

10.1016/s1470-2045(19)30668-0

Cite this

Petrylak, DP., de Wit, R., Chi, KN., Drakaki, A., Sternberg, CN., Nishiyama, H., Castellano, D., Hussain, SA., Flechon, A., Bamias, A., Yu, EY., van der Heijden, MS., Matsubara, N., Alekseev, B., Necchi, A., Geczi, L., Ou, YC., Coskun, HS., Su, WP., ... Powles, T. (2020). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, 21(1), 105-120. https://doi.org/10.1016/s1470-2045(19)30668-0

@article{6b2b79be92534ab78107931d7265ffb7,

title = "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial",

author = "DP Petrylak and {de Wit}, Ronald and KN Chi and A Drakaki and CN Sternberg and H Nishiyama and D Castellano and SA Hussain and A Flechon and A Bamias and EY Yu and {van der Heijden}, MS and N Matsubara and B Alekseev and A Necchi and L Geczi and YC Ou and HS Coskun and WP Su and J Bedke and G Gakis and IJ Percent and JL Lee and M Tucci and A Semenov and F Laestadius and A Peer and G Tortora and S Safina and {del Muro}, XG and A Rodriguez-Vida and I Cicin and H Harputluoglu and ST Tagawa and U Vaishampayan and JB Aragon-Ching and O Hamid and AM Liepa and S Wijayawardana and F Russo and RA Walgren and AH Zimmermann and RR Hozak and KM Bell-McGuinn and T Powles",

year = "2020",

doi = "10.1016/s1470-2045(19)30668-0",

language = "Undefined/Unknown",

volume = "21",

pages = "105--120",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "1",

}

Petrylak, DP, de Wit, R, Chi, KN, Drakaki, A, Sternberg, CN, Nishiyama, H, Castellano, D, Hussain, SA, Flechon, A, Bamias, A, Yu, EY, van der Heijden, MS, Matsubara, N, Alekseev, B, Necchi, A, Geczi, L, Ou, YC, Coskun, HS, Su, WP, Bedke, J, Gakis, G, Percent, IJ, Lee, JL, Tucci, M, Semenov, A, Laestadius, F, Peer, A, Tortora, G, Safina, S, del Muro, XG, Rodriguez-Vida, A, Cicin, I, Harputluoglu, H, Tagawa, ST, Vaishampayan, U, Aragon-Ching, JB, Hamid, O, Liepa, AM, Wijayawardana, S, Russo, F, Walgren, RA, Zimmermann, AH, Hozak, RR, Bell-McGuinn, KM & Powles, T 2020, 'Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial', Lancet Oncology, vol. 21, no. 1, pp. 105-120. https://doi.org/10.1016/s1470-2045(19)30668-0

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. / Petrylak, DP; de Wit, Ronald; Chi, KN et al.
In: Lancet Oncology, Vol. 21, No. 1, 2020, p. 105-120.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

AU - Petrylak, DP

AU - de Wit, Ronald

AU - Chi, KN

AU - Drakaki, A

AU - Sternberg, CN

AU - Nishiyama, H

AU - Castellano, D

AU - Hussain, SA

AU - Flechon, A

AU - Bamias, A

AU - Yu, EY

AU - van der Heijden, MS

AU - Matsubara, N

AU - Alekseev, B

AU - Necchi, A

AU - Geczi, L

AU - Ou, YC

AU - Coskun, HS

AU - Su, WP

AU - Bedke, J

AU - Gakis, G

AU - Percent, IJ

AU - Lee, JL

AU - Tucci, M

AU - Semenov, A

AU - Laestadius, F

AU - Peer, A

AU - Tortora, G

AU - Safina, S

AU - del Muro, XG

AU - Rodriguez-Vida, A

AU - Cicin, I

AU - Harputluoglu, H

AU - Tagawa, ST

AU - Vaishampayan, U

AU - Aragon-Ching, JB

AU - Hamid, O

AU - Liepa, AM

AU - Wijayawardana, S

AU - Russo, F

AU - Walgren, RA

AU - Zimmermann, AH

AU - Hozak, RR

AU - Bell-McGuinn, KM

AU - Powles, T

PY - 2020

Y1 - 2020

U2 - 10.1016/s1470-2045(19)30668-0

DO - 10.1016/s1470-2045(19)30668-0

M3 - Article

SN - 1470-2045

VL - 21

SP - 105

EP - 120

JO - Lancet Oncology

JF - Lancet Oncology

IS - 1

ER -

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology. 2020;21(1):105-120. doi: 10.1016/s1470-2045(19)30668-0